TOP TEN perturbations for P57071 (Homo sapiens)

Organism: Homo sapiens
Gene: P57071
Selected probe(set): 230777_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of P57071 (230777_s_at) across 5779 perturbations tested by GENEVESTIGATOR:

DLBCL study 7 (ABC; naive-like) / DLBCL study 7 (ABC; memory-like)

Relative Expression (log2-ratio):3.5270262
Number of Samples:2 / 5
Experimental DLBCL study 7 (ABC; naive-like)
Primary tumor samples from patients with diffuse large B-cell lymphoma (activated B-cell like type). Samples were also classified based on subset-specific B-cell-associated gene signature (BAGS) and assigned to naive-like group. Patients were treated according to standard protocols, and comparable doses of RCHOP- like regimens were used. No patient was treated with stem cell transplantation.
Control DLBCL study 7 (ABC; memory-like)
Primary tumor samples from patients with diffuse large B-cell lymphoma (activated B-cell like type). Samples were also classified based on subset-specific B-cell-associated gene signature (BAGS) and assigned to memory-like group. Patients were treated according to standard protocols, and comparable doses of RCHOP- like regimens were used. No patient was treated with stem cell transplantation.

DLBCL study 7 (ABC; unclassified) / DLBCL study 7 (ABC; naive-like)

Relative Expression (log2-ratio):-3.4460793
Number of Samples:3 / 2
Experimental DLBCL study 7 (ABC; unclassified)
Primary tumor samples from patients with diffuse large B-cell lymphoma (activated B-cell like type). Samples were not classified based on subset-specific B-cell-associated gene signature (BAGS) and labeled as unclassified. Patients were treated according to standard protocols, and comparable doses of RCHOP- like regimens were used. No patient was treated with stem cell transplantation.
Control DLBCL study 7 (ABC; naive-like)
Primary tumor samples from patients with diffuse large B-cell lymphoma (activated B-cell like type). Samples were also classified based on subset-specific B-cell-associated gene signature (BAGS) and assigned to naive-like group. Patients were treated according to standard protocols, and comparable doses of RCHOP- like regimens were used. No patient was treated with stem cell transplantation.

HCC study 20 (CDX; Hep-G2; ectopic) / HCC study 20 (PDX; ectopic)

Relative Expression (log2-ratio):2.9296494
Number of Samples:3 / 11
Experimental HCC study 20 (CDX; Hep-G2; ectopic)
Tumor tissue biopsy samples from Hep-G2 cell line-derived xenograft (CDX) ectopically generated in SCID mice by injecting hepatocellular carcinoma cells subcutaneously. In order to establish ectopic models, cells were injected subcutaneously into the flank regions. The mice were euthanized after two weeks.
Control HCC study 20 (PDX; ectopic)
Tumor tissue biopsy samples from patient-derived xenograft (PDX) sample ectopically generated in SCID mice by injecting hepatocellular carcinoma cells subcutaneously. Donor tumor tissue was obtained intraoperatively during liver resection from three patients. All three patients had hepatocellular carcinoma confirmed by histology. In order to establish ectopic models, cells were injected subcutaneously into the flank regions. The mice were euthanized after two weeks.

DLBCL study 1 (activated B-cell like; memory-like) / DLBCL study 1 (activated B-cell like; centroblast-like)

Relative Expression (log2-ratio):-2.8841686
Number of Samples:3 / 3
Experimental DLBCL study 1 (activated B-cell like; memory-like)
Memory B-cells sorted from primary tumor samples from patients with malignant diffuse large B-cell lymphoma (activated B-cell like type). To isolate different B-cell subsets, tonsil tissues from DLBCL patients were sorted by fluorescence-activated cell sorting. Samples were also classified based on subset-specific B-cell-associated gene signature (BAGS).
Control DLBCL study 1 (activated B-cell like; centroblast-like)
Centroblast B-cells sorted from primary tumor samples from patients with malignant diffuse large B-cell lymphoma (activated B-cell like type). To isolate different B-cell subsets, tonsil tissues from DLBCL patients were sorted by fluorescence-activated cell sorting. Samples were also classified based on subset-specific B-cell-associated gene signature (BAGS).

B-CLL study 11 (DMSO) / vehicle (DMSO) treated normal B-cell sample

Relative Expression (log2-ratio):2.8767033
Number of Samples:4 / 4
Experimental B-CLL study 11 (DMSO)
Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with vehicle (DMSO) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l.
Control vehicle (DMSO) treated normal B-cell sample
MACS purified resting B-cells from healthy donor peripheral blood treated with vehicle (DMSO) for 4 hours.

DLBCL study 7 (ABC; plasmablast-like) / DLBCL study 7 (ABC; naive-like)

Relative Expression (log2-ratio):-2.8217754
Number of Samples:11 / 2
Experimental DLBCL study 7 (ABC; plasmablast-like)
Primary tumor samples from patients with diffuse large B-cell lymphoma (activated B-cell like type). Samples were also classified based on subset-specific B-cell-associated gene signature (BAGS) and assigned to plasmablast-like group. Patients were treated according to standard protocols, and comparable doses of RCHOP- like regimens were used. No patient was treated with stem cell transplantation.
Control DLBCL study 7 (ABC; naive-like)
Primary tumor samples from patients with diffuse large B-cell lymphoma (activated B-cell like type). Samples were also classified based on subset-specific B-cell-associated gene signature (BAGS) and assigned to naive-like group. Patients were treated according to standard protocols, and comparable doses of RCHOP- like regimens were used. No patient was treated with stem cell transplantation.

B-CLL study 11 (rolipram) / rolipram study 4 (normal B-cell; 20uM)

Relative Expression (log2-ratio):2.5783405
Number of Samples:4 / 4
Experimental B-CLL study 11 (rolipram)
Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l. ATC code:---
Control rolipram study 4 (normal B-cell; 20uM)
MACS purified resting B-cells from healthy donor peripheral blood treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. ATC code:---

DLBCL study 1 (germinal center B-cell like; plasmablast-like) / DLBCL study 1 (germinal center B-cell like; centroblast-like)

Relative Expression (log2-ratio):-2.4139557
Number of Samples:3 / 14
Experimental DLBCL study 1 (germinal center B-cell like; plasmablast-like)
Plasmablast B-cells sorted from primary tumor samples from patients with malignant diffuse large B-cell lymphoma (germinal center B-cell like type). To isolate different B-cell subsets, tonsil tissues from DLBCL patients were sorted by fluorescence-activated cell sorting. Samples were also classified based on subset-specific B-cell-associated gene signature (BAGS).
Control DLBCL study 1 (germinal center B-cell like; centroblast-like)
Centroblast B-cells sorted from primary tumor samples from patients with malignant diffuse large B-cell lymphoma (germinal center B-cell like type). To isolate different B-cell subsets, tonsil tissues from DLBCL patients were sorted by fluorescence-activated cell sorting. Samples were also classified based on subset-specific B-cell-associated gene signature (BAGS).

AsPC-1 / BxPC-3

Relative Expression (log2-ratio):2.229783
Number of Samples:3 / 3
Experimental AsPC-1
Human xenograft derived metastatic cancer cell line derived from mouse xenografts initiated with metastatic cells from the ascites derived from a 62 years old female Caucasian patient with pancreatic adenocarcinoma. Synonyms:AsPc-1; Aspc-1; ASPC-1; As-PC1; ASPC1; AsPC1; Aspc1; AsPc1 Cellosaurus code:
Control BxPC-3
Human pancreatic adenocarcinoma cell line derived from a 61 years old female patient. Synonyms:BxPc-3; BXPC-3; Bx-PC3; BXPC3; BxPC3; BxPc3 Cellosaurus code:

DLBCL study 1 (activated B-cell like; plasmablast-like) / DLBCL study 1 (activated B-cell like; centroblast-like)

Relative Expression (log2-ratio):-2.2217407
Number of Samples:12 / 3
Experimental DLBCL study 1 (activated B-cell like; plasmablast-like)
Plasmablast B-cells sorted from primary tumor samples from patients with malignant diffuse large B-cell lymphoma (activated B-cell like type). To isolate different B-cell subsets, tonsil tissues from DLBCL patients were sorted by fluorescence-activated cell sorting. Samples were also classified based on subset-specific B-cell-associated gene signature (BAGS).
Control DLBCL study 1 (activated B-cell like; centroblast-like)
Centroblast B-cells sorted from primary tumor samples from patients with malignant diffuse large B-cell lymphoma (activated B-cell like type). To isolate different B-cell subsets, tonsil tissues from DLBCL patients were sorted by fluorescence-activated cell sorting. Samples were also classified based on subset-specific B-cell-associated gene signature (BAGS).